Usted buscó: immunoġeniċita (Maltés - Inglés)

immunoġeniċita
immunogenicity

studji ta’ immunoġeniċita fuq adulti ≥18-il sena u l-anzjani
immunogenicity studies in adults ≥18 years and the elderly

l- immunoġeniċita ’ ma gietx studjata fl- istudju dwar mard tal- qalb kongenitali.
12 immunogenicity was not studied in the congenital heart disease study.

għadu m’ hux disponibbli tagħrif dwar immunoġeniċita fit- tul wara l- użu ta ’ menitorix bħala vaċċin primarju jew booster
long-term immunogenicity data following the use of menitorix as a primary and booster vaccination are not yet available (see section 5.1).

ma giet innutata l-ebda differenza bejn il-gruppi fiż-żewġ studji, għall dak li jirrigwarda l-immunoġeniċita’.
no difference between groups regarding immunogenicity was observed in either study.

f’test open label prospettiv, li ġie maħsub biex ikunu evalwati l-farmakokinetika, is-sigurta u l- immunoġeniċita` wara li jingħataw 7 dożi ta’ palivizumab fi staġun wieħed ta’ rsv, informazzjoni farmakokinetika indikat li ntlaħqu livelli medji adegwati ta’ palivizumab fit-18-il tifel/tifla kollha li ħadu sehem.
in an open label prospective trial designed to evaluate pharmacokinetics, safety and immunogenicity after administration of 7 doses of palivizumab within a single rsv season, pharmacokinetic data indicated that adequate mean palivizumab levels were achieved in all 18 children enrolled.